Columbia Striant approved
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Columbia Labs will launch its novel testosterone replacement patch Striant (testosterone buccal system) third quarter 2003, the firm said. FDA cleared the product June 19 for treatment of conditions associated with a deficiency or absence of endogenous testosterone, including hypogonadism. The firm will "immediately expand its existing sales force to 135 professionals who will add endocrinologists, urologists and a select group of primary care physicians to their current target list of OB/GYNs." Distribution, managed care and thought leader programs are underwa